Cargando…

Utility of a Molecular Signature for Predicting Recurrence and Progression in Non-Muscle-Invasive Bladder Cancer Patients: Comparison with the EORTC, CUETO and 2021 EAU Risk Groups

To evaluate the utility of different risk assessments in non-muscle-invasive bladder cancer (NMIBC) patients, a total of 178 NMIBC patients from Chungbuk National University Hospital (CBNUH) were enrolled, and the predictive value of the molecular signature-based subtype predictor (MSP888) and risk...

Descripción completa

Detalles Bibliográficos
Autores principales: Piao, Xuan-Mei, Kim, Seon-Kyu, Byun, Young Joon, Zheng, Chuang-Ming, Kang, Ho Won, Kim, Won Tae, Kim, Yong-June, Lee, Sang-Cheol, Kim, Wun-Jae, Moon, Sung-Kwon, Choi, Yung Hyun, Yun, Seok Joong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9696895/
https://www.ncbi.nlm.nih.gov/pubmed/36430959
http://dx.doi.org/10.3390/ijms232214481
_version_ 1784838422740860928
author Piao, Xuan-Mei
Kim, Seon-Kyu
Byun, Young Joon
Zheng, Chuang-Ming
Kang, Ho Won
Kim, Won Tae
Kim, Yong-June
Lee, Sang-Cheol
Kim, Wun-Jae
Moon, Sung-Kwon
Choi, Yung Hyun
Yun, Seok Joong
author_facet Piao, Xuan-Mei
Kim, Seon-Kyu
Byun, Young Joon
Zheng, Chuang-Ming
Kang, Ho Won
Kim, Won Tae
Kim, Yong-June
Lee, Sang-Cheol
Kim, Wun-Jae
Moon, Sung-Kwon
Choi, Yung Hyun
Yun, Seok Joong
author_sort Piao, Xuan-Mei
collection PubMed
description To evaluate the utility of different risk assessments in non-muscle-invasive bladder cancer (NMIBC) patients, a total of 178 NMIBC patients from Chungbuk National University Hospital (CBNUH) were enrolled, and the predictive value of the molecular signature-based subtype predictor (MSP888) and risk calculators based on clinicopathological factors (EORTC, CUETO and 2021 EAU risk scores) was compared. Of the 178 patients, 49 were newly analyzed by the RNA-sequencing, and their MSP888 subtype was evaluated. The ability of the EORTC, MSP888 and two molecular subtyping systems of bladder cancer (Lund and UROMOL subtypes) to predict progression of 460 NMIBC patients from the UROMOL project was assessed. Cox regression analyses showed that the MSP888 was an independent predictor of NMIBC progression in the CBNUH cohort (p = 0.043). Particularly in patients without an intravesical BCG immunotherapy, MSP888 significantly linked with risk of disease recurrence and progression (both p < 0.05). However, the EORTC, CUETO and 2021 EAU risk scores showed disappointing results with respect to estimating the NMIBC prognosis. In the UROMOL cohort, the MSP888, Lund and UROMOL subtypes demonstrated a similar capacity to predict NMIBC progression (all p < 0.05). Conclusively, the MSP888 is favorable for stratifying patients to facilitate optimal treatment.
format Online
Article
Text
id pubmed-9696895
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-96968952022-11-26 Utility of a Molecular Signature for Predicting Recurrence and Progression in Non-Muscle-Invasive Bladder Cancer Patients: Comparison with the EORTC, CUETO and 2021 EAU Risk Groups Piao, Xuan-Mei Kim, Seon-Kyu Byun, Young Joon Zheng, Chuang-Ming Kang, Ho Won Kim, Won Tae Kim, Yong-June Lee, Sang-Cheol Kim, Wun-Jae Moon, Sung-Kwon Choi, Yung Hyun Yun, Seok Joong Int J Mol Sci Article To evaluate the utility of different risk assessments in non-muscle-invasive bladder cancer (NMIBC) patients, a total of 178 NMIBC patients from Chungbuk National University Hospital (CBNUH) were enrolled, and the predictive value of the molecular signature-based subtype predictor (MSP888) and risk calculators based on clinicopathological factors (EORTC, CUETO and 2021 EAU risk scores) was compared. Of the 178 patients, 49 were newly analyzed by the RNA-sequencing, and their MSP888 subtype was evaluated. The ability of the EORTC, MSP888 and two molecular subtyping systems of bladder cancer (Lund and UROMOL subtypes) to predict progression of 460 NMIBC patients from the UROMOL project was assessed. Cox regression analyses showed that the MSP888 was an independent predictor of NMIBC progression in the CBNUH cohort (p = 0.043). Particularly in patients without an intravesical BCG immunotherapy, MSP888 significantly linked with risk of disease recurrence and progression (both p < 0.05). However, the EORTC, CUETO and 2021 EAU risk scores showed disappointing results with respect to estimating the NMIBC prognosis. In the UROMOL cohort, the MSP888, Lund and UROMOL subtypes demonstrated a similar capacity to predict NMIBC progression (all p < 0.05). Conclusively, the MSP888 is favorable for stratifying patients to facilitate optimal treatment. MDPI 2022-11-21 /pmc/articles/PMC9696895/ /pubmed/36430959 http://dx.doi.org/10.3390/ijms232214481 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Piao, Xuan-Mei
Kim, Seon-Kyu
Byun, Young Joon
Zheng, Chuang-Ming
Kang, Ho Won
Kim, Won Tae
Kim, Yong-June
Lee, Sang-Cheol
Kim, Wun-Jae
Moon, Sung-Kwon
Choi, Yung Hyun
Yun, Seok Joong
Utility of a Molecular Signature for Predicting Recurrence and Progression in Non-Muscle-Invasive Bladder Cancer Patients: Comparison with the EORTC, CUETO and 2021 EAU Risk Groups
title Utility of a Molecular Signature for Predicting Recurrence and Progression in Non-Muscle-Invasive Bladder Cancer Patients: Comparison with the EORTC, CUETO and 2021 EAU Risk Groups
title_full Utility of a Molecular Signature for Predicting Recurrence and Progression in Non-Muscle-Invasive Bladder Cancer Patients: Comparison with the EORTC, CUETO and 2021 EAU Risk Groups
title_fullStr Utility of a Molecular Signature for Predicting Recurrence and Progression in Non-Muscle-Invasive Bladder Cancer Patients: Comparison with the EORTC, CUETO and 2021 EAU Risk Groups
title_full_unstemmed Utility of a Molecular Signature for Predicting Recurrence and Progression in Non-Muscle-Invasive Bladder Cancer Patients: Comparison with the EORTC, CUETO and 2021 EAU Risk Groups
title_short Utility of a Molecular Signature for Predicting Recurrence and Progression in Non-Muscle-Invasive Bladder Cancer Patients: Comparison with the EORTC, CUETO and 2021 EAU Risk Groups
title_sort utility of a molecular signature for predicting recurrence and progression in non-muscle-invasive bladder cancer patients: comparison with the eortc, cueto and 2021 eau risk groups
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9696895/
https://www.ncbi.nlm.nih.gov/pubmed/36430959
http://dx.doi.org/10.3390/ijms232214481
work_keys_str_mv AT piaoxuanmei utilityofamolecularsignatureforpredictingrecurrenceandprogressioninnonmuscleinvasivebladdercancerpatientscomparisonwiththeeortccuetoand2021eauriskgroups
AT kimseonkyu utilityofamolecularsignatureforpredictingrecurrenceandprogressioninnonmuscleinvasivebladdercancerpatientscomparisonwiththeeortccuetoand2021eauriskgroups
AT byunyoungjoon utilityofamolecularsignatureforpredictingrecurrenceandprogressioninnonmuscleinvasivebladdercancerpatientscomparisonwiththeeortccuetoand2021eauriskgroups
AT zhengchuangming utilityofamolecularsignatureforpredictingrecurrenceandprogressioninnonmuscleinvasivebladdercancerpatientscomparisonwiththeeortccuetoand2021eauriskgroups
AT kanghowon utilityofamolecularsignatureforpredictingrecurrenceandprogressioninnonmuscleinvasivebladdercancerpatientscomparisonwiththeeortccuetoand2021eauriskgroups
AT kimwontae utilityofamolecularsignatureforpredictingrecurrenceandprogressioninnonmuscleinvasivebladdercancerpatientscomparisonwiththeeortccuetoand2021eauriskgroups
AT kimyongjune utilityofamolecularsignatureforpredictingrecurrenceandprogressioninnonmuscleinvasivebladdercancerpatientscomparisonwiththeeortccuetoand2021eauriskgroups
AT leesangcheol utilityofamolecularsignatureforpredictingrecurrenceandprogressioninnonmuscleinvasivebladdercancerpatientscomparisonwiththeeortccuetoand2021eauriskgroups
AT kimwunjae utilityofamolecularsignatureforpredictingrecurrenceandprogressioninnonmuscleinvasivebladdercancerpatientscomparisonwiththeeortccuetoand2021eauriskgroups
AT moonsungkwon utilityofamolecularsignatureforpredictingrecurrenceandprogressioninnonmuscleinvasivebladdercancerpatientscomparisonwiththeeortccuetoand2021eauriskgroups
AT choiyunghyun utilityofamolecularsignatureforpredictingrecurrenceandprogressioninnonmuscleinvasivebladdercancerpatientscomparisonwiththeeortccuetoand2021eauriskgroups
AT yunseokjoong utilityofamolecularsignatureforpredictingrecurrenceandprogressioninnonmuscleinvasivebladdercancerpatientscomparisonwiththeeortccuetoand2021eauriskgroups